Form 4: Sonnet BioTherapeutics CEO Reports Merger Stock Exchange

Sonnet BioTherapeutics Holdings, Inc. CEO Raghu Rao reported the exchange of 22,356 vested restricted stock units for Hyperliquid Strategies Inc. common stock and CVRs following a business combination.

Summary

• Raghu Rao, Chief Executive Officer and Director of Sonnet BioTherapeutics Holdings, Inc., reported a transaction on December 2, 2025, related to a business combination.
• The transaction occurred pursuant to a Business Combination Agreement (BCA) dated July 11, 2025, involving Sonnet BioTherapeutics, Rorschach I LLC, and Hyperliquid Strategies Inc (HSI).
• As a result of the merger, Rorschach became a direct wholly-owned subsidiary of HSI, and Sonnet BioTherapeutics became a direct wholly-owned subsidiary of HSI.
• The transaction involved 22,356 shares of Common Stock, representing vested restricted stock units (RSUs) held by Mr. Rao.
• These RSUs included 20,000 granted on July 11, 2025, which vested at the effective time of the Company Merger, and 2,356 previously vested RSUs.
• Each restricted stock unit was exchanged for one-fifth of a share of HSI Common Stock and one Contingent Value Right (CVR).
• All reported amounts reflect prior reverse stock splits of Sonnet BioTherapeutics: 1:22 effective August 31, 2023, and 1:8 effective September 30, 2024.

Sentiment

Score: 5

Explanation: The filing is a factual report of an insider transaction following a corporate merger, providing no explicit positive or negative sentiment regarding future performance or operational results.

Positives

• The successful completion of the Business Combination Agreement indicates a strategic transaction for Sonnet BioTherapeutics, leading to its acquisition by Hyperliquid Strategies Inc.
• Restricted stock units held by the CEO, Raghu Rao, vested as a result of the merger, converting into HSI Common Stock and CVRs, providing value realization for the insider.

Negatives

• Sonnet BioTherapeutics Holdings, Inc. is now a direct wholly-owned subsidiary of Hyperliquid Strategies Inc., indicating a loss of independent public company status.

Future Outlook

This filing reports a completed transaction and does not provide forward-looking statements or guidance regarding future performance or strategic direction.

Industry Context

The reported merger signifies a consolidation event, a common strategic move in the biotechnology or pharmaceutical industry, often aimed at combining assets, pipelines, or market reach. The specific implications for the broader industry are not detailed in this insider transaction report.

Related Party Transactions

• The transaction involves the CEO, Raghu Rao, exchanging his vested restricted stock units for securities of the acquiring entity, Hyperliquid Strategies Inc., as part of a broader business combination.

Stakeholder Impact

• Shareholders of Sonnet BioTherapeutics Holdings, Inc. would have had their shares exchanged for Hyperliquid Strategies Inc. Common Stock and Contingent Value Rights (CVRs) as part of the merger.
• Employees holding restricted stock units, such as the CEO, saw their units vest and convert into HSI securities, realizing value from their equity compensation.

Key Dates

Keywords

Sonnet BioTherapeutics, Hyperliquid Strategies Inc, Merger, Business Combination, SEC Form 4, Insider Transaction, Restricted Stock Units, CVR, Raghu Rao